Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

ClinicalTrials.gov ID: NCT04958785

Public ClinicalTrials.gov record NCT04958785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Study identification

NCT ID
NCT04958785
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gilead Sciences
Industry
Enrollment
92 participants

Conditions and interventions

Interventions

  • Magrolimab Drug
  • Nab-Paclitaxel Drug
  • Paclitaxel Drug
  • Sacituzumab Govitecan-hziy Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 13, 2021
Primary completion
Oct 7, 2024
Completion
Oct 7, 2024
Last update posted
Nov 3, 2025

2021 – 2024

United States locations

U.S. sites
19
U.S. states
11
U.S. cities
19
Facility City State ZIP Site status
Mayo Clinic Phoenix Arizona 85054
Women's Cancer Care Fresno California 93710
Providence Medical Foundation Fullerton California 92835
University of California San Francisco San Francisco California 94115
Saint John's Cancer Institute Santa Monica California 90404
Providence Medical Foundation Santa Rosa California 95403
Mayo Clinic Jacksonville Florida 32224
University Cancer & Blood Center,LLC Athens Georgia 30607
Winship Cancer Institute Emory University Atlanta Georgia 30322
Southeastern Regional Medical Center, LLC Newnan Georgia 30265
Orchard Healthcare Research Inc Skokie Illinois 60077
Ochsner Clinic Foundation New Orleans Louisiana 70121
Allina Health Cancer Institute Minneapolis Minnesota 55407
Mayo Clinic Rochester Minnesota 55905
Astera Cancer Care East Brunswick New Jersey 08816
NYU Investigational Pharmacy, Laura & Isaac Perlmutter Cancer Center New York New York 10016
Stony Brook University Stony Brook New York 11794
Charleston Oncology Charleston South Carolina 29414
Huntsman Cancer Institute, University of Utah Salt Lake City Utah 84112

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04958785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 3, 2025 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04958785 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →